Orthocell (ASX:OCC) achieved the first commercial sales of its nerve repair product, Remplir, in Thailand, according to a Monday Australian bourse filing.
This follows the appointment of MediTime as the company's exclusive in-country distributor for Remplir in the country. Orthocel is supporting the launch and is working with MediTime to train representatives and build engagement.
Its shares rose 2% in recent trading on Monday.